Vir Biotechnology, Inc. Retained Earnings
Vir Biotechnology, Inc. (VIR) had Retained Earnings of -$1.24 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-05
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$1.24B.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$1.32B.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$1.20B.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$1.15B.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$1.24B 10-Q · filed 2026-08-05 |
| 2026-03-31 | -$1.32B 10-Q · filed 2026-05-07 |
| 2025-12-31 | -$1.20B 10-Q · filed 2026-08-05 |
| 2025-09-30 | -$1.15B 10-Q · filed 2025-11-05 |
| 2025-06-30 | -$991.71M 10-Q · filed 2025-08-06 |
| 2025-03-31 | -$880.75M 10-Q · filed 2025-05-08 |
| 2024-12-31 | -$759.78M 10-K · filed 2026-02-23 |
| 2024-09-30 | -$655.20M 10-Q · filed 2024-11-04 |
| 2024-06-30 | -$441.48M 10-Q · filed 2024-08-01 |
| 2024-03-31 | -$303.10M 10-Q · filed 2024-05-03 |
| 2023-12-31 | -$237.82M 10-K · filed 2025-02-27 |
| 2023-09-30 | -$121.85M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $41.56M 10-Q · filed 2023-08-04 |
| 2023-03-31 | $236.34M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $377.24M 10-K · filed 2024-02-26 |
| 2022-09-30 | $478.84M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $303.53M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $380.02M 10-Q · filed 2022-05-05 |
| 2021-12-31 | -$138.60M 10-K · filed 2023-02-28 |
| 2021-09-30 | -$663.85M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $774.28M 10-Q · filed 2021-08-05 |
| 2021-03-31 | -$836.10M 10-Q · filed 2021-05-06 |
| 2020-12-31 | -$667.18M 10-K · filed 2022-02-28 |
| 2020-09-30 | -$561.53M 10-Q · filed 2020-11-10 |
| 2020-06-30 | -$476.93M 10-Q · filed 2020-08-11 |
| 2020-03-31 | -$445.76M 10-Q · filed 2020-05-12 |
| 2019-12-31 | -$368.52M 10-K · filed 2021-02-25 |
| 2019-09-30 | -$304.75M 10-Q · filed 2019-11-19 |
| 2018-12-31 | -$193.84M 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |